Citron Research tweeted on July 19 that AbbVie is the next great drug short. $ABBV the next great drug short. TGT price $60 Gottlieb’s comments for biosimilars and the removal of safe harbor is a DIRECT hit on Abbvie’s abuse… Read More
The concern with AbbVie’s blockbuster biologic Humira is the lost of patent exclusivity in the U.S. and Europe over the next two years. The worry is revenue from Humira will drop off a cliff as generic drugs enter the market…. Read More
There is a common misconception with AbbVie (ABBV) in regards to its blockbuster drug Humira. Sure Dividend outlines this misconception below. That’s where the risk with AbbVClie comes in. The company’s composition-of-matter patent for Humira expires at the end of… Read More
This is from the AMM Dividend Letter released February 28, 2014. If you want to see the latest “Dividend Stock in Focus” as soon as it’s released then join our mailing list here. You’ve probably never heard the story of… Read More
For those of you who have been paying into Social Security for your entire working careers, the day when you finally retire and begin